"The price is high for a drug that can do so many things well"
LOL. Even if brilacidin could do even one thing well - and that remains to be proven - the entire market cap of IPIX is $22.4 million.
Twenty times that would represent the fingernail scrapings from a Big Pharma CEO's weekly manicure if they wanted to buy brilacidin or the whole company.
Brilacidin has had a "for sale" sign on it for years now.
One look at the Data Room is all it takes for anyone who knows about pharmaceuticals to avert their eyes in horror.
Granted the price would be high but I would have to believe that a large pharma company can afford a drug who some believe would be a new SOC. I mean pharma deals have been made for compounds that have been thru a Phase II and in some rare instances a Phase I trial.
Market Data 
Markets 
AI
